WuXiUP – Continuous Biomanufacturing Platform with Ultra-high Productivity
The WuXiUP process platform is a key breakthrough in biologics continuous manufacturing. A single 1,000 L disposable bioreactor can produce more than 30 kg of mAb per batch while delivering similar purification yields as compared to traditional purification processes. Using the WuXiUP platform, approximately 500 kg of mAb therapeutics could be produced per year providing similar productivity as traditional 10,000-20,000 L stainless steel bioreactors. Other WuXiUP features include:
-
Process technology platform that couples Repligen XCell™ ATF System technology with continuous direct product capture
-
Ideal not only for labile or difficult to express proteins but also mAbs, Fc-fusion proteins etc.
-
Enabling higher productivity with rapid development, scale-up and implementation at large scales
-
Continuous approach effectively reduces manufacturing cost of goods
Comparison with traditional fed-batch
-
Achieving roughly same production cell culture timelines with 5-10X yield with high cell concentrations, viability and better or comparable product quality profiles
-
Tunable glycan and charge variance profiles, usually with reduced HMW and LMW
-
Able to reduce media consumption and harvest volume due to higher viable cell concentrations (VCC) and lower cell specific perfusion rates
-
Higher production facility efficiencies leading to lower COGs
Lab scale
Pilot scale (non-GMP)
Clinical GMP production
Commercial GMP production
